

Synthesis of New Conjugated Mesomeric Betaines from Alkoxy-carbonylazinium Salts

Jesús Valenciano^a, Ana M. Cuadro^a, Juan. J. Vaquero^a, José L. García-Navío^a, Julio Alvarez-Builla^{a*}, Pilar Gómez-Sal^b and Avelino Martín^b

^aDepartamento de Química Orgánica and ^bDepartamento de Química Inorgánica, Universidad de Alcalá, 28871-Alcalá de Henares, Madrid, Spain.

Abstract: A new series of conjugated mesomeric betaines have been synthesized from the reaction of various aminoheterocycles with 2-methylthio-4-oxo-3-phenylpyrido[2,1-f][1,2,4]triazinium iodide, itself prepared from 2-ethoxycarbonylpyridinium N-aminide. Some of the heterobetaines and salts obtained have been studied by ¹H-NMR, and their structures have been confirmed by X-ray analysis. The crystal structures reveal unexpected complementary stabilizing interactions between some betaines and their salts. Copyright © 1996 Published by Elsevier Science Ltd

INTRODUCTION

Heterocyclic mesomeric betaines¹ have been the subject of extensive investigation, mainly because of their 1,3-dipolar character (**1**), which allows them to take part in 1,3-dipolar cycloadditions with various dipolarophiles, thus generating novel five-membered aza heterocycles.² As 1,4-dinucleophiles (**2**), heterobetaines can react with 1,2-dicarbonyl compounds³ to give a variety of azonia derivatives possessing a quaternary bridgehead nitrogen. However, apart from a few examples in the literature which describe the reactivity of 2-carbonylpyridinium N-aminides with nitriles, and the dimerization of 2-cyano-, 2-alkoxycarbonyl- and 2-aroil-N-aminoazinium salts⁴, little is known about their behavior as 1,4-nucleophile-electrophiles (**3**) (Figure 1).





Figure 1

In an earlier paper we reported an example of this 1,4-nucleophilic-electrophilic character of 2-alkoxycarbonylazinium-N-ylides and N-aminides,^{5a} which on reaction with heterocumulenes in a [4+2] cyclocondensation process gave rise to new conjugated mesomeric betaines **5** containing the system pyrido[2,1-*f*][1,2,4]triazinium^{5b}. These N-ylides however, also behave as 1,3-dipoles when reacted with DMAD to afford the corresponding cycloadducts **4** (Scheme 1).




Scheme 1

As an extension of this preliminary work, we wish to report here the transformation of heterobetaines **5** into a new class of conjugated mesomeric betaines whose structure has been studied by X-ray diffraction.

RESULTS AND DISCUSSION


The azinium N-aminides⁶ **3**, which were readily generated from 2-alkoxycarbonylazinium salts, reacted with phenyl isocyanate and isothiocyanate affording the corresponding heterobetaines **5** in good yields. Subsequent S-methylation of the 4-oxo-3-phenylpyrido[2,1-*f*][1,2,4]triazinium-2-thiolate **5a** afforded the corresponding salt **6** (Scheme 2). The displacement of the methylthio group⁷ by various heterocycles was examined with an eye towards generating new heterobetaines where the negative charge would be extensively delocalized over the attached heterocyclic moiety. Thus, **6** was reacted with 2-aminothiazole, 2-aminobenzothiazole, and 2-amino-1,3,4-thiadiazole in the presence of K_2CO_3/CH_3CN to give the expected mesomeric conjugated betaines **7a-c** in good yields. However, when **6** was reacted with the hydrate of 2-aminotetrazole under the same conditions, it was extensively transformed into the corresponding 4-oxo-3-phenylpyrido[2,1-*f*][1,2,4]triazinium-2-olate **5b**. When anhydrous 2-aminotetrazole was used, unreacted **6** was recovered with none of the desired betaine being observed, even after prolonged refluxing. After several unsuccessful attempts ($Et_3N/EtOH$, K_2CO_3/CH_2Cl_2 , Et_3N/DMF), the heterobetaine **7d** could be formed (26%) in the presence of diisopropylethylamine (Hunig's base), after 48 h reflux, with an appreciable amount of **6** also being recovered. The use of a large excess of 2-aminotetrazole seemed to moderately improve the yield of **7d**, as interpreted from the 1H NMR analysis of the crude mixture. However, the difficulty associated with the work-up of the reaction mixture led to a similar low yield of the isolated compound (Scheme 2).



Scheme 2

When the nucleophilic displacement of the methylthio group in **6** was attempted using 2-aminobenzimidazole, different reaction products were found depending on the conditions used (Scheme 3). Thus, in the absence of base the 2-(benzimidazole-2-ylidenamino-4-oxo-3-phenylpyrido[2,1-*f*]-[1,2,4]triazinium iodide **8a** was isolated in 83% yield, which upon treatment with K_2CO_3 was transformed into the mesomeric conjugated betaine **7f**. However, when the reaction of **6** with 2-aminobenzimidazole was performed in the presence of base (K_2CO_3/CH_3CN), the betaine **7e** was obtained, which was rapidly converted into **7f** in the presence of protic solvents such as ethanol, or slowly in aprotic polar solvents such as DMSO or acetonitrile. Additionally, salt **8a** could be obtained by treating **7f** with 57% hydriodic acid in methanol.

The structures of **8a** and **7f** were initially assigned on the basis of their characteristic 1H -NMR data. Compounds **7e** and **7f** exhibit somewhat different 1H -NMR spectra. The chemical shifts of the protons assigned to the pyridinium moiety of **7f** show four well-resolved signals starting at $\delta=9.27$ ppm. The benzo-protons of the benzimidazole display an asymmetrical pattern, and the NH proton appears as a singlet at $\delta=11.44$ ppm. Compound **7e** however, shows relatively high field signals with the most shielded proton of the pyridinium moiety appearing at $\delta=8.43$ ppm. The aromatic ring protons of benzimidazole resonate as AA'BB' multiplets, and the NH proton shows up at $\delta=12.6$ ppm. Finally, compound **8a** presents two equivalent NH protons at $\delta=12.46$ ppm and an overlapping of the signals corresponding to benzimidazolyl and pyridyl ring protons.




Scheme 3

Methylation of **7f** with methyl iodide gave the salt **9**, which could alternatively be obtained in a two-step transformation by reacting **6** with 2-amino-1-methylbenzimidazole, followed by treatment with hydriodic acid in methanol. These conversions provide further support for the structures assigned to **7f** and **8a**, which were finally confirmed by X-ray analysis. Figures 2 and 3 represent the structures of **7f** and **8a**, and give the corresponding labelling scheme, while Figures 4 and 5 show the unit cells for both compounds, and show some of the more relevant intermolecular interactions.


The molecular structures of compounds **7f** and **8a** are very similar. Figures 2 and 3 show that both the betaine **7f** and the salt **8a** are virtually planar, the angle between the main plane of the benzimidazole ring and the main plane of the pyrido[2,1-*f*]triazinium system being $8.1(2)^\circ$ in **7f**, and $3.7(4)^\circ$ in **8a**. The phenyl group is twisted in both compounds, $98.2(2)^\circ$ in **7f** and $61.4(6)^\circ$ in **8a**.

In the betaine **7f**, the distances from the exocyclic nitrogen to the contiguous carbon atoms are slightly different, (N(4)-C(2)=1.31(1)Å and N(4)-C(8)=1.37(1)Å), showing some preference for the location of the double bond between N(4) and C(2). The other distances confirm extensive delocalization within the structure, with all the C-N distances being very similar. A comparable situation exists for **8a**, and an analysis of the distances does not allow us to locate any multiple bond. X-ray analyses confirm intramolecular hydrogen bonds in both compounds **7f** (N(5)-N(2)=2.63(1) Å) and **8a** (N(3)-N(5)= 2.70(2) Å).




Figures 2 and 3. ORTEP drawing of compounds **7f** and **8a** with atomic numbering scheme.

Compounds **7f** and **8a** crystallize in a triclinic crystal system, in which one molecule of methanol and ethanol are incorporated respectively. Figure 4 shows the unit cell of **7f** and the intermolecular hydrogen bonding interaction between N(6) of the benzimidazole ring and the oxygen atom of the solvent ($N(6)-O(2)=2.78(1)\text{\AA}$). Figure 5 shows a similar effect in **8a**, although the interaction is weaker ($N(6)-O(2)=3.02(2)\text{\AA}$).



Figures 4 and 5. Unit cell packing of compounds **7f** and **8a** showing relevant intermolecular interactions.

Surprisingly, when 2-aminoimidazole was reacted with **6** the precipitate obtained was not the expected heterobetaine **7h** but the structure **10**, in which the betaine is strongly associated to its corresponding salt through a hydrogen bond between two imidazole nitrogens (Scheme 4).



Scheme 4

Although the 1H NMR of the compound presented some of the characteristics associated with the heterobetaines **7**, microanalysis strongly suggested it to have a "dimeric" structure and the presence of a single iodide ion. X-ray analysis confirmed the proposed structure, whose three-dimensional view and unit cell packing in are shown in Figure 6 and 7 respectively.


Figure 6 gives a perspective view of **10**. From this the "dimeric" structure arranged around a proton, which is situated at the center of a hydrogen bond in a symmetry center between two equal molecules, is evident. Consequently, there is one iodide counterion for each dimer. This ion shows some crystallographic disorder and we have found two different positions for it with occupancies of 90% and 10%.

The "dimeric" structure is virtually planar, with an angle between the main plane of the imidazole ring and the main plane of the pyrido[2,1-f]triazinium system of $15.2(2)^\circ$ and $11.6(2)^\circ$ in each half of the structure, and thus shows some loss of planarity with respect to compounds **7f** and **8a**. The phenyl group is twisted $106.4(2)^\circ$ and $90.7(2)^\circ$ from the plane of the bicyclic system in each molecule. These small differences between both molecules are probably due to the crystalline packing, as no significant differences are apparent in the bond distances. As was observed in **7f** and **8a**, the X-ray analysis showed intramolecular interactions N(12)-N(16) ($2.635(5)\text{Å}$) and N(1)-N(6) ($2.716(9)\text{Å}$).

The crystal and experimental details of the structure determination of compounds **7f**, **8a** and **10** are presented in Table 1.

Table 1. Crystal data and structure refinement for **7f**, **8a** and **10**.

| | 7f | 8a | 10 |
|--|--|---|--|
| Empirical formula | C ₂₀ H ₁₄ N ₆ O.CH ₃ OH | C ₂₀ H ₁₅ IN ₆ O.C ₂ H ₅ OH | C ₃₂ H ₂₆ IN ₁₂ O ₂ .CH ₃ CN |
| Molecular weight | 386.41 | 528.34 | 762.59 |
| Temperature (K) | | 293(2) | |
| Wavelength (Å) | | 0.71073 | |
| Crystal system | Triclinic | Triclinic | Triclinic |
| Space group | P-1 | P-1 | P-1 |
| a(Å), a(°) | 8.567(3), 85.52(5) | 6.889(5), 108.31(5) | 8.175(2), 101.44(3) |
| b(Å), b(°) | 10.074(7), 73.25(4) | 12.964(7), 94.08(5) | 11.647(2), 91.41(3) |
| c(Å), g(°) | 12.461(8), 65.73(4) | 13.156(6), 104.55(5) | 18.281(4), 97.40(3) |
| Volume(Å ³) | 937.8(9) | 1065(1) | 1689.6(6) |
| Z | 2 | 2 | 2 |
| D _{calc} (gcm ⁻³) | 1.368 | 1.644 | 1.530 |
| Absorption coefficient (mm ⁻¹) | 0.093 | 1.515 | 1.001 |
| F(000) | 404 | 527 | 786 |
| Crystal size (mm) | 0.25 x 0.20 x 0.20 | 0.25 x 0.20 x 0.15 | 0.40 x 0.36 x 0.28 |
| θ range for data collection | 2 to 27° | 2 to 27° | 2.60 to 24.77° |
| Index ranges | -10<H<10, -12<K<12, 0<L<15 | -8<H<8, -15<K<15, -0<L<15 | 0<H<9, -13<K<13, -21<L<21 |
| Reflections collected | 4338 | 4003 | 6261 |
| Independent reflections | 4099 | 3834 | 5734 |
| Refinement method | | Full matrix least-squares on F ² | |
| Data/restraints/parameters | 4077/0/308 | 3826/0/284 | 5725/0/456 |
| Goodness-of-fit on F ² | 1.102 | 1.126 | 1.084 |
| Final R indices, reflections | R1=0.093, wR2=0.136(1129) | R1=0.125, wR2=0.344(2238) | R1=0.055, wR2=0.128(3351) |
| [I>2σ(I)] | | | |
| Weighting scheme | calc | calc | calc |
| P=(F _o ² +2F _c ²)/3 | w=1/[σ ² (F _o ²)+(0.0003P) ² + 3.5654P] | w=1/[σ ² (F _o ²)+(0.1851P) ² + 41.8267P] | w=1/[σ ² (F _o ²)+(0.0549P) ² + 4.9028P] |
| Largest diff. peak and hole (eÅ ⁻³) | 0.403 and -0.279 | 2.190 and -2.693 | 1.060 and -0.647 |



10

Figures 6 and 7. ORTEP drawing and unit cell packing of compound **10**.

A similar structure to **10** was obtained in the reaction of **6** with 2-amino-5,6-dimethylbenzimidazole, as shown in Scheme 4. Treatment of **6** with an excess of the aminoheterocycle in acetonitrile at room temperature resulted in the formation of the salt **8b** (80%) which, when treated with K_2CO_3 yielded a precipitate that was identified as **11**. The 1H NMR spectrum of compound **10** shows a singlet corresponding to the C3 and C4 imidazole protons at $\delta=6.82$ ppm, thus indicating a symmetrical structure. This symmetry is also evident in compound **11** where both methyl substituents resonate as a singlet at $\delta=2.22$ ppm. Generally speaking, it can be said that all those compounds possessing both acidic hydrogens and electron-rich nitrogens should easily associate through intra or intermolecular hydrogen bonds, depending on the solvent and the pH of the medium, with the generation of a more stable crystalline structure being the driving force.

In conclusion, the nucleophilic displacement of the methylthio group in 2-methylthio-4-oxo-3-phenylpyrido[2,1-*f*][1,2,4]triazinium iodide by aminoheterocycles allowed the straightforward synthesis of various mesomeric conjugated heterocyclic betaines. Small variations in the nature of the aminoheterocycle were seen to lead to unexpected molecular associations arising from strong hydrogen bonding interactions.

EXPERIMENTAL SECTION

Melting points were determined on an Electrothermal IA6304 apparatus. Infrared spectra were recorded on a Perkin-Elmer 1310 spectrophotometer using KBr pellets. ^1H NMR spectra were recorded on a Varian Unity 300 instrument. Mass spectra were determined on a Hewlett-Packard 5988A (70 eV) spectrometer. X-ray calculations were performed on an ALPHA AXP (Digital) Workstation. Column chromatography was performed on silica gel, SDS (0.035-0.070 mm). 4-Oxo-3-phenylpyrido[2,1-*f*][1,2,4]triazinium-2-thiolate (**5a**) and 2-methylthio-4-oxo-3-phenylpyrido[2,1-*f*][1,2,4]triazinium iodide (**6**) were prepared using our previously described method^{5a}. All other chemicals are commercially available.

General Procedure for the Preparation of 4-Oxo-3-phenylpyrido[2,1-*f*][1,2,4]triazinium-2-azolates Inner Salts (7). To a stirred suspension of 2-methylthio-4-oxo-3-phenylpyrido[2,1-*f*][1,2,4]triazinium iodide **6** (0.40 g, 1 mmol) and the corresponding 2-aminoheterocycle (1.1 mmol) in dry acetonitrile (10 mL), anhydrous K_2CO_3 (0.55 g, 4 mmol) was added. The reaction mixture was stirred at room temperature for 48 h and the solvent was removed to dryness. The residue was then triturated with water (3x1 mL) and the resulting precipitate was filtered, washed with water until neutral and crystallized as indicated.

7a. Following the general procedure, using 2-aminothiazole, 0.25 g (78%) of **7a** was isolated as orange prisms: mp 306-307 °C (DMF); IR (KBr) 1685, 1530, 1446, 1401, 1245, 1188 cm^{-1} ; ^1H NMR (DMSO- d_6) δ 8.84-8.81 (m, 1H), 8.38-8.35 (m, 1H), 8.05-8.01 (m, 2H), 7.54-7.50 (m, 2H), 7.47-7.43 (m, 1H), 7.33-7.30 (m, 2H), 7.23 (d, 1H, $J = 3.7$ Hz), 7.02 (d, 1H, $J = 3.7$ Hz). Anal. Calcd for $\text{C}_{16}\text{H}_{11}\text{N}_5\text{OS}$: C, 59.80; H, 3.45; N, 21.79; S, 9.98. Found: C, 59.51; H, 3.26; N, 21.50; S, 9.69.

7b. Following the general procedure, from 2-aminothiadiazole, **7b** was isolated as yellow microprisms (0.23 g, 72%): mp 311-312 °C (DMF); IR (KBr) 1687, 1530, 1495, 1430, 1398, 1299, 1230, 1184, 1145 cm^{-1} ; ^1H NMR (DMSO- d_6) δ 8.96 (s, 1H), 8.90-8.87 (m, 1H), 8.42-8.38 (m, 1H), 8.12-8.05 (m, 2H), 7.57-7.42 (m, 3H), 7.34-7.30 (m, 2H). Anal. Calcd for $\text{C}_{15}\text{H}_{10}\text{N}_6\text{OS}$: C, 55.89; H, 3.13; N, 26.07; S, 9.95. Found: C, 55.61; H, 2.92; N, 25.78; S, 9.67.

7c. Following the general procedure, from 2-aminobenzothiazole, work-up of the mixture gave **7c** (0.36 g, 97%) as orange prisms: mp 336-337 °C (DMF); IR (KBr) 1697, 1538, 1500, 1477, 1441, 1293 cm^{-1} ; ^1H NMR (DMSO- d_6) δ 8.94-8.90 (m, 1H), 8.43-8.37 (m, 1H), 8.13-8.05 (m, 2H), 7.72 (dd, 1H, $J = 7.7, 0.7$ Hz), 7.57-7.42 (m, 4H), 7.37-7.33 (m, 2H), 7.26-7.19 (m, 1H), 7.11-7.05 (m, 1H); MS (m/z) 371 (M^+ , 21), 78 (100). Anal. Calcd for $\text{C}_{20}\text{H}_{13}\text{N}_5\text{OS}$: C, 64.68; H, 3.53; N, 18.86; S, 8.63. Found: C, 64.54; H, 3.25; N, 18.58; S, 8.39.

7d. Diisopropylethylamine (0.7 mL, 4 mmol) was added to a stirred suspension of **6** (0.40 g, 1 mmol) and 2-aminotetrazole (0.1 g, 1 mmol) in dry acetonitrile (15 mL). After 48 h reflux, the solvent was removed and the residue was purified by column chromatography on silica gel using acetone:methanol (9.5:0.5) as eluent. Crystallization gave **7d** (0.08 g, 26%) as yellow needles: mp 273-274 °C (EtOH); IR (KBr) 1710, 1548, 1517, 1492, 1441, 1098 cm^{-1} ; ^1H NMR (DMSO- d_6) δ 14.50 (s, 1H), 9.41 (dd, 1H, $J = 4.0, 2.6$ Hz), 8.38 (dd, 1H, $J = 7.7, 1.8$ Hz), 8.18-8.05 (m, 2H), 7.55-7.41 (m, 3H), 7.33-7.28 (m, 2H). Anal. Calcd for $\text{C}_{14}\text{H}_{10}\text{N}_8\text{O}$: C, 54.90;

H, 3.29; N, 36.58. Found: C, 54.92; H, 3.43; N, 36.91.

7e. This compound was prepared from **6** (0.40 g, 1 mmol) and 2-aminobenzimidazole (0.15 g, 1.1 mmol) following the general procedure. Purification gave 0.31 g (89%) of **7e** as dark red prisms: mp 242-243 °C (DMF); IR (KBr) 3245, 1685, 1599, 1566, 1442, 1202, 1148 cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 12.58 (s, 1H), 8.43 (d, 1H, *J* = 6.2 Hz), 8.23 (dd, 1H, *J* = 7.7, 1.8 Hz), 7.84-7.78 (m, 1H), 7.76-7.69 (m, 1H), 7.63-7.56 (m, 2H), 7.27-7.20 (m, 2H), 7.14-7.07 (m, 2H), 6.95-6.90 (m, 2H), 6.82-6.76 (m, 1H); MS (*m/z*) 354 (M⁺, 39), 78 (100). Anal. Calcd for C₂₀H₁₄N₆O: C, 67.79; H, 3.98; N, 23.72. Found: C, 67.52; H, 3.82; N, 23.46.

7f. To a suspension containing **8a** (0.48 g, 1 mmol) in acetonitrile (10 mL) anhydrous K₂CO₃ (0.55 g, 4 mmol) was added. The general procedure then gave 0.26 g (75%) of **7f** as orange needles: mp 304-305 °C (EtOH); IR (KBr) 1703, 1619, 1541, 1447, 1413, 1281, 1235, 1192, 1163 cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 11.44 (s, 1H), 9.27 (d, 1H, *J* = 6.6 Hz), 8.34 (dd, 1H, *J* = 8.1, 1.8 Hz), 8.13-8.07 (m, 1H), 8.01-7.95 (m, 1H), 7.55-7.16 (m, 7H), 6.95-6.89 (m, 2H); MS (*m/z*) 354 (M⁺, 51), 235 (15), 78 (100). Anal. Calcd for C₂₀H₁₄N₆O.1EtOH: C, 65.99; H, 5.03; N, 20.99. Found: C, 66.30; H, 5.14; N, 20.98.

7g. From 2-amino-1-methyl-benzimidazole, following the general procedure, **7g** (0.32 g, 86%) was obtained as dark red needles: mp 237-238 °C (acetone); IR (KBr) 1704, 1607, 1578, 1440, 1181, 1147 cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 8.43 (d, 1H, *J* = 6.2 Hz), 8.22 (dd, 1H, *J* = 7.7, 1.8 Hz), 7.83-7.70 (m, 2H), 7.67-7.60 (m, 2H), 7.36-7.23 (m, 2H), 7.14-7.08 (m, 2H), 6.94-6.90 (m, 2H), 6.83-6.76 (m, 1H), 3.78 (s, 3H). MS (*m/z*) 368 (M⁺, 11), 221 (5), 118 (13), 78 (100). Anal. Calcd for C₂₁H₁₆N₆O: C, 68.45; H, 4.38; N, 22.81. Found: C, 68.37; H, 4.03; N, 22.98.

Synthesis of the Dimers **10** and **11**.

10. Following the general procedure, anhydrous K₂CO₃ (8 mmol) was added to **6** and 2-aminoimidazole hydrogen sulphate (0.39 g, 1.5 mmol) and the mixture was stirred at room temperature for 48 h under argon. The mixture was filtered to provide **10** as dark red prisms (0.33 g, 43%): mp 284-285 °C (CH₃CN); IR (KBr) 1702, 1623, 1548, 1446, 1299, 1266, 1198 cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 11.82 (s, 1H), 9.25 (d, 1H, *J* = 6.6 Hz), 8.36 (dd, 1H, *J* = 7.9, 1.7 Hz), 8.16-8.10 (m, 1H), 8.04 (t, 1H, *J* = 7.9 Hz), 7.54-7.40 (m, 3H), 7.30 (d, 2H, *J* = 7.7 Hz), 6.82 (s, 2H). Anal. Calcd for C₃₂H₂₃IN₁₂O₂.CH₃CN: C, 52.52; H, 3.63; N, 23.42. Found: C, 52.43; H, 3.62; N, 23.31.

11. A suspension containing **8b** (0.51g, 1 mmol) and anhydrous K₂CO₃ (0.55 g, 4 mmol) in acetonitrile (10 mL) was submitted to the general procedure, and after the usual work-up gave 0.31 g of **11** (70%) as brown needles: mp 262-263 °C (CH₂Cl₂); IR (KBr) 2919, 2851, 1697, 1628, 1558, 1446, 1418, 1300, 1214, 1195 cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 11.24 (s, 1H), 9.24 (d, 1H, *J* = 6.2 Hz), 8.32 (dd, 1H, *J* = 8.1, 1.8 Hz), 8.11-8.05 (m, 1H), 7.95 (td, 1H, *J* = 7.7, 1.1 Hz), 7.55-7.40 (m, 3H), 7.33-7.29 (m, 2H), 7.08-6.98 (m, 2H), 2.22 (s, 6H). Anal. Calcd for C₄₄H₃₇IN₁₂O₂: C, 59.20; H, 4.18; N, 18.83. Found: C, 59.35; H, 4.35; N, 18.84.

Synthesis of 2-(Benzimidazole-2-ylidenamino)-4-oxo-3-phenylpyrido[2,1-*f*][1,2,4]triazinium Salts (**8**).

8a. A suspension of **6** (0.40g, 1 mmol) and 2-aminobenzimidazole (0.40 g, 3 mmol) in dry acetonitrile (15 mL) was stirred for 20 h at room temperature. The reaction mixture was filtered to furnish **8a** as yellow

needles (0.40 g, 83%): mp 318-319 °C (EtOH); IR (KBr) 1708, 1622, 1580, 1522, 1477, 1434, 1301, 1270 cm^{-1} ; ^1H NMR (DMSO- d_6) δ 12.46 (s, 2H), 9.58-9.55 (m, 1H), 8.61-8.57 (m, 1H), 8.42-8.36 (m, 2H), 7.61-7.35 (m, 7H), 7.30-7.24 (m, 2H). MS (m/z) 354 (M^+ , 15), 235 (9), 128 (94). Anal. Calcd for $\text{C}_{20}\text{H}_{15}\text{IN}_6\text{O}$: C, 49.81; H, 3.13; N, 17.42. Found: C, 49.60; H, 3.02; N, 17.13.

8b. A suspension of **6** (0.40 g, 1 mmol) and 2-amino-5,6-dimethylbenzimidazole (0.48 g, 3 mmol) in acetonitrile (10 mL) was stirred at room temperature for 48 h. The solvent was removed to dryness and the residue was triturated with ethanol (3x1 mL). The solid formed was collected and crystallized, yielding **8b** (0.41 g, 80%) as orange needles: mp 235-236 °C (EtOH); IR (KBr) 1697, 1623, 1553, 1484, 1445, 1300, 1195 cm^{-1} ; ^1H NMR (DMSO- d_6) δ 12.15 (s, 1H), 9.48 (d, 1H, $J = 5.9$ Hz), 8.52 (dd, 1H, $J = 7.3, 2.2$ Hz), 8.33-8.27 (m, 2H), 7.58-7.33 (m, 5H), 7.15 (s, 2H), 2.26 (s, 6H). Anal. Calcd for $\text{C}_{22}\text{H}_{19}\text{IN}_6\text{O}$: C, 51.78; H, 3.75; N, 16.47. Found: C, 51.50; H, 4.10; N, 16.16.

9. Method A. To a suspension of **7f** (0.35 g, 1 mmol) in EtOAc (5 mL), methyl iodide (0.5 mL, 8 mmol) was added. The mixture was stirred for 24 h at room temperature and the precipitate was isolated by filtration yielding **9** (0.42 g, 87%) as yellow needles.

9. Method B. To a suspension of 0.37 g (1 mmol) of the heterobetaine **7g** in methanol (10 mL), 0.13 mL of 57% HI were added dropwise after cooling to 0°C. The mixture was then stirred for 5 min. Filtration provided **9** as yellow needles (0.45 g, 91%): mp 332-333°C (EtOH); IR (KBr) 1708, 1625, 1583, 1537, 1482, 1453, 1306 cm^{-1} ; ^1H NMR (DMSO- d_6) δ 12.30 (s, 1H), 9.55-9.51 (m, 1H), 8.65-8.60 (m, 1H), 8.43-8.38 (m, 2H), 7.61-7.28 (m, 9H), 3.20 (s, 3H). Anal. Calcd for $\text{C}_{21}\text{H}_{17}\text{IN}_6\text{O}$: C, 50.82; H, 3.45; N, 16.93. Found: C, 51.03; H, 3.27; N, 16.77.

Single-Crystal X-Ray Structure Determination of Compounds 7f, 8a and 10. Intensity data were collected using a CAD4 diffractometer with graphite-monochromated $\text{MoK}\alpha$ radiation (0.71073 Å). Data were collected at room temperature. Intensities were corrected for Lorentz and polarization effects in the usual manner. No absorption or extinction corrections were made.

The structures were solved by direct methods using SHELX-86⁸ and refined by full matrix least-square analysis on F^2 with SHELXL-93⁹. Non hydrogen atoms were anisotropically refined. When the quality of data allowed, hydrogen atoms were found by Fourier difference synthesis and refined isotropically, but in most cases hydrogen atoms were introduced from geometrical calculations in the last cycle of refinement with fixed thermal parameters. The solution of the structure for the dimeric compound indicated the iodide anion to exist in two different positions with occupancies of 90% I(1) and 10% I(1').

ACKNOWLEDGMENTS

We wish to express our thanks to the Comisió Interdepartamental de Recerca i Innovació Tecnològica (CIRIT) for financial support (Project QFN94-4619) and to the Ministerio de Educación y Ciencia for a grant to one of us (JVM).

REFERENCES

1. Ollis, W. D.; Stanforth, S. P. *Tetrahedron* **1985**, *41*, 714.
2. (a) Padwa, A. in *1,3-Dipolar Cycloaddition Chemistry*, Vol. 2, *General Heterocyclic Chemistry Series*, ed. Taylor, E.C.; Weissberger, A.; J. Wiley & Sons, N.Y. **1984**. (b) Boekelheide, V.; Fedoruk, N. A.; *J. Org. Chem.* **1968**, *33*, 2062.
3. For examples see: (a) Westphal, O.; Jahn, K.; Heffe, W. E. *Arch. Pharm.* **1961**, *294*, 37. (b) Matia, M. P.; Garcia, J. L.; Vaquero, J. J.; Alvarez-Builla, J. *J. Heterocyclic Chem.* **1990**, *27*, 661. (c) Matia, M. P.; Ezquerro, J.; Sanchez-Ferrando, F.; Garcia, J. L.; Vaquero, J. J.; Alvarez-Builla, J. *Tetrahedron* **1991**, *47*, 7329. (d) Matia, M. P.; Ezquerro, J.; Sanchez-Ferrando, F.; Garcia, J. L.; Vaquero, J. J.; Alvarez-Builla, J. *Tetrahedron Lett.* **1991**, *32*, 7575. (e) Hajós, G.; Messmer, A.; Bátor, S.; Riedl, Z. *Bull. Soc. Chem. Belg.* **1992**, *101*, 597. (f) Hajós, G.; Riedl, Z.; Gács-Baitz, E.; Messmer, A. *Tetrahedron* **1992**, *48*, 8459. (g) Matia, M. P.; Garcia, J. L.; Vaquero, J. J.; Alvarez-Builla, J. *Liebigs Ann. Chem.* **1992**, 777. (h) Santesteban, I.; Siro, J. G.; Vaquero, J. J.; Garcia-Navio, J. L.; Alvarez-Builla, J.; Castaño, O. *J. Org. Chem.* **1995**, *60*, 5667. (i) Diaz, A.; Matia, M. P.; Garcia, J. L.; Vaquero, J. J.; Alvarez-Builla, J. *J. Org. Chem.* **1995**, *59*, 8294.
4. For examples see: (a) Bátor, S.; Juhász-Riedl, Zs.; Sandor, P.; Messmer, A. *J. Heterocyclic Chem.* **1986**, *23*, 375. (b) Bátor, S.; Messmer, A. *J. Heterocyclic Chem.* **1988**, *25*, 437. (c) Bátor, S.; Hajós, G.; Sándor, P.; Messmer, A. *J. Org. Chem.* **1989**, *54*, 3062. (d) Bátor, S.; Messmer, A. *J. Heterocyclic Chem.* **1990**, *27*, 1673.
5. (a) Cuadro, A. M.; Valenciano, J.; Vaquero, J. J.; Garcia, J. L.; Alvarez-Builla, J. *Tetrahedron* **1993**, *49*, 3185. (b) Kakehi, A.; Ito, S.; Uchiyama, K.; Konno, Y.; Kondo, K. *J. Org. Chem.* **1977**, *42*, 443.
6. (a) Alcalde, E. in *Adv. Heterocycl. Chem.* **1995**, *60*, 198 and references therein. (b) Alcalde, E.; Gisbert, M.; Pérez-García, L. *Tetrahedron* **1995**, *51*, 13365.
7. (a) de Pablo, M. S.; Gandasegui, T.; Vaquero, J. J.; Garcia-Navio, J. L.; Alvarez-Builla, J. *Tetrahedron* **1992**, *48*, 8793. (b) Newton, C. G.; Ollis, W. D.; Wright, D. *J. Chem. Soc., Perkin Trans. I.* **1984**, 69.
8. Sheldrick, G.M. *Acta Cryst. A* **1990**, *46*, 467.
9. Sheldrick, G.M. SHELXL-93, University of Göttingen, **1993**.

(Received in UK 17 June 1996; revised 8 July 1996; accepted 11 July 1996)